Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics' Ambitious 5-Year Plan: Double Sales With New VNS Components

This article was originally published in The Gray Sheet

Executive Summary

Cyberonics aims to double its sales to $320 million over the next five years by improving and adding new features to its VNS Therapy vagus nerve stimulation implant and entering new markets like Japan

You may also be interested in...



Business News In Brief

Roche snaps up BioImagene: Digital pathology laboratory equipment maker BioImagene is acquired by diagnostics firm Roche for $100 million under an agreement announced Aug. 23. BioImagene systems generate high-resolution, whole-slide digital images from glass microscope slides and incorporate software for image analysis. The deal builds on Roche's $3.4 billion acquisition in 2008 of tissue-based cancer test maker Ventana Medical Systems (1"The Gray Sheet" Jan. 28, 2008). By adding privately held BioImagene, Roche/Ventana "is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," the company said. "With BioImagene's current and future products, we will be able to deliver an end-to-end solution from automated staining to comprehensive patient reports.

Business News In Brief

Roche snaps up BioImagene: Digital pathology laboratory equipment maker BioImagene is acquired by diagnostics firm Roche for $100 million under an agreement announced Aug. 23. BioImagene systems generate high-resolution, whole-slide digital images from glass microscope slides and incorporate software for image analysis. The deal builds on Roche's $3.4 billion acquisition in 2008 of tissue-based cancer test maker Ventana Medical Systems (1"The Gray Sheet" Jan. 28, 2008). By adding privately held BioImagene, Roche/Ventana "is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," the company said. "With BioImagene's current and future products, we will be able to deliver an end-to-end solution from automated staining to comprehensive patient reports.

Cyberonics' VNS Therapy gains approval in Japan

Cyberonics plans to launch its VNS Therapy vagus nerve stimulation device in Japan for drug-resistant epilepsy once it receives final reimbursement authorization, the company said in announcing marketing clearance from Japan's Ministry of Health, Labor and Welfare on Jan. 19. The Japanese market entry is part of Cyberonics' plan to double sales within five years, the company said last month (1"The Gray Sheet" Dec. 14, 2009)

Related Content

Topics

UsernamePublicRestriction

Register

MT028267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel